• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

ODs reach for artificial tears first to treat dry eye

Article

In a poll fielded on the Optometry Times website, we asked ODs what treatment option they choose first when managing dry eye patients.

View the poll here

A total of 185 responses were tallied. The multiple-choice poll answers included:

• Amniotic membrane
• Artificial tears
• IPL
• Lid therapy
• Meibomian gland device treatments (LipiFlow, BlephEx, iLux, NuLlids)
• Nasal stimulation devices (True Tear)
• Punctal plugs
• Rx drops (Restasis, Xiidra)
• Steroids

Related: Explore the relationship between dry eye and sleep

The majority of respondents look to artificial tears to treat dry eye with 66 percent choosing them first.

Lid therapy was second choice, but the choice was not close. Only 17 percent of respondents look to address the lids first.

After another sharp drop, Rx drops come in third with 8 percent of respondents opting for this therapy to begin treatment.

Related: Ophthalmic community focusing on DED education

Meibomian gland device treatments are fourth with 5 percent of ODs, then steroids and punctal plugs tie for fifth place with 2 percent of respondents.

IPL hits seventh place with only 1 percent of ODs choosing this option first.

Amniotic membrane and nasal stimulation tie for last place with 0 votes for them.

Related: Understanding prevalence, demographics of dry eye disease

Related Videos
Marc R Bloomenstein, OD, FAAO, chats with Optometry Times about the benefits of Vevye in the treatment of dry eye
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
© 2024 MJH Life Sciences

All rights reserved.